KalVista Pharmaceuticals (FRA:4XC1) EV-to-EBIT : -3.32 (As of May. 27, 2024)

KalVista Pharmaceuticals EV-to-EBIT Chart

KalVista Pharmaceuticals Annual Data
	Trend	Dec14	Apr15	Apr16	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23
EV-to-EBIT		Get a 7-Day Free Trial					-9.95	-3.17	-6.33	-1.60	-1.36

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EV-to-EBIT	Get a 7-Day Free Trial															-1.02	-1.36	-2.03	-1.67	-3.86

Competitive Comparison of KalVista Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, KalVista Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's EV-to-EBIT falls into.

KalVista Pharmaceuticals EV-to-EBIT Calculation

KalVista Pharmaceuticals's EV-to-EBIT for today is calculated as:

KalVista Pharmaceuticals's current Enterprise Value is €377.89 Mil.
KalVista Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-113.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KalVista Pharmaceuticals  (FRA:4XC1) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

KalVista Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

KalVista Pharmaceuticals's Enterprise Value for the quarter that ended in Jan. 2024 was €404.49 Mil.
KalVista Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-113.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KalVista Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (FRA:4XC1) Business Description